Coherus Biosciences
Coherus Biosciences focuses on developing and commercializing next-generation immuno-oncology therapies, including the FDA-approved LOQTORZI™ for nasopharyngeal carcinoma and multiple investigational therapeutics in clinical trials.
Company Overview
Coherus Biosciences specializes in developing and commercializing next-generation immuno-oncology therapies. Its scientific platform includes cutting-edge analytics, immunology, clinical, and regulatory expertise. The company has a diversified pipeline of immuno-oncology drug candidates targeting the tumor microenvironment. Headquartered in Redwood City, California, with additional lab facilities in Camarillo, Coherus Biosciences provides extensive patient assistance and support programs.
FDA-Approved Therapies
Coherus Biosciences' LOQTORZI™ (toripalimab-tpzi) is the first and only FDA-approved therapy for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). This therapy can be administered in combination with chemotherapy or as a single agent. Additional FDA designations include Orphan Drug and Fast Track for casdozokitug, a novel anti-IL-27 antibody for refractory hepatocellular carcinoma.
Clinical Trials
Coherus Biosciences conducts multiple ongoing clinical trials across various cancer indications. Key investigational immuno-oncology therapeutics include Casdozokitug for lung and liver cancer, currently in Phase 1/2 clinical trials, and CHS-114, an ADCC-enhanced anti-CCR8 antibody being tested alone and with toripalimab in patients with advanced solid tumors. Preclinical candidate CHS-1000 targets the immune suppressive ILT4 pathway.
Biosimilar Products
Coherus Biosciences markets two notable biosimilar products: UDENYCA®, an oncology biosimilar, and YUSIMRY™, which is used in immunology. These products provide alternative treatment options while maintaining effectiveness, giving patients access to high-quality, potentially cost-saving therapies.
Patient Support Programs
Committed to patient care, Coherus Biosciences offers extensive patient assistance and office support to ensure access and reimbursement for their therapies. Their total rewards program includes competitive base salary, performance-based target bonuses, stock options, and comprehensive healthcare coverage, paying 90% of premiums for employees and 85% for dependents. The company also has programs for clinical, technical, and scientific education, and supports healthcare-related events through its Educational Grants Portal.